AATec Medical GmbH, a Munich-based biotechnology company, has raised four million euros in a pre-Series A financing round. The company develops therapeutic approaches for chronic inflammatory and infectious respiratory diseases based on recombinant alpha-1 antitrypsin (AAT). The investors include Federal Agency for Disruptive Innovations (Sprind) as well as several private investors, industry experts and single family offices.
The capital inflow will be used to further develop the lead drug candidate ATL-105, which is intended for the targeted treatment of non-cystic fibrosis (NCFB). This chronic inflammatory lung disease affects over three million people in Western countries and is currently treated exclusively symptomatically. Targeted drug therapy currently does not exist.
The funding will enable ATL-105 to be prepared for clinical development by 2026. The goal is to create a causal and locally effective treatment option for NCFB. Preclinical data indicate a high safety profile and broad therapeutic potential.
Innovative approach to an urgent medical problem
Dr. Rüdiger Jankowsky, CEO and co-founder of AATec Medical, explains:
"This funding is an important step in preparing ATL-105 for clinical trials. Non-cystic fibrosis (NCFB) significantly impacts patients' quality of life, and current treatment options are limited. We believe ATL-105 has the potential to offer significant therapeutic advances to millions of patients worldwide. In Western countries alone, more than three million patients suffer from NCFB. With our innovative protein inhalation approach, we deliver ATL-105 directly to the lungs, the central site of disease progression. This maximizes efficacy and minimizes the risk of systemic side effects. Sprind's support validates our innovative approach and underscores the transformative potential of our technology."
Sprind sees AATec Medical’s development as a pioneering solution to a key public health challenge. Sigrid Koeth, Innovation Manager at Spring says:
"At Sprind, we look for ideas that have the potential to fundamentally change things for the better. We believe AATec Medical's approach with recombinant alpha-1 antitrypsin offers great potential for a broad spectrum of respiratory diseases and infections. Such innovations can make a significant contribution to public health and strengthen the resilience of our healthcare systems."
